Abstract 1571
Background
Papillary carcinoma is the most common type of thyroid cancer and if it is not treated early, it can spread throughout the body. Therefore, the first line of treatment for papillary thyroid cancer is the surgery by removing part of or the entire thyroid. Our study aims to establish the most effective surgical procedure (total thyroidectomy or partial thyroidectomy) to achieve better survival for stage I and II papillary carcinoma and evaluate the effect of the ethnicity, sex and age on patients' survival undergoing these surgical techniques.
Methods
We extracted the data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries. We retrieved data of 3691 patients diagnosed with papillary thyroid cancer in 2010. We evaluated the 5-year overall survival of patients using the log-rank test. Patients were grouped into two groups. The first one underwent thyroid lobectomy (242) and the second underwent total thyroidectomy (3449). Patients were further grouped according to ethnicity (white, black, American or Asian), sex (female or male) and age group.
Results
We found that total thyroidectomy was associated with better 5-year overall survival rates in patients with early stage papillary carcinoma, compared to lobectomy (98.1% and 96.5%, respectively, P = 0.021). Moreover, total thyroidectomy showed better survival rates in females than males (98.6% and 95.7%, respectively, p = 0.000) and in young patients aged between 20-39 years (99.8%, p = 0.000). Meanwhile, surgical techniques were not significantly associated with patients’ ethnicity.
Conclusions
Total thyroidectomy was superior to lobectomy in early stages papillary thyroid carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sara Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4653 - Impact of Pembrolizumab (pembro) Versus Paclitaxel on Health-Related Quality of Life (HRQoL) in Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer That Has Progressed After First-Line Chemotherapy (KEYNOTE-061)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract
5063 - Does Nutritional Status Affect Treatment Tolarability, Response and Survival in Metastatic Gastric Cancer Patients? Results of Prospective Multicenter Study
Presenter: Senem Karabulut
Session: Poster Display session 2
Resources:
Abstract
2717 - Ramucirumab use in patients with Advanced Gastric Cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
Presenter: Federico Longo Munoz
Session: Poster Display session 2
Resources:
Abstract
3187 - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy
Presenter: Takaki Yoshikawa
Session: Poster Display session 2
Resources:
Abstract
4765 - A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab based therapy
Presenter: Qian Li
Session: Poster Display session 2
Resources:
Abstract
3500 - Randomised phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (SEED)
Presenter: Peter Petersen
Session: Poster Display session 2
Resources:
Abstract
5197 - Ramucirumab in the treatment of refractory metastatic gastric cancer: results from the RamSelGa trial.
Presenter: Alexey Tryakin
Session: Poster Display session 2
Resources:
Abstract
2011 - Regorafenib in combination with Paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): a phase Ib trial with expansion cohort
Presenter: Mohammed Khurshed
Session: Poster Display session 2
Resources:
Abstract
2117 - The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials
Presenter: Wataru Ichikawa
Session: Poster Display session 2
Resources:
Abstract
2669 - A Phase 1b Study of Oraxol in Combination with Ramucirumab in Patients with Gastric or Esophageal Cancers who failed previous chemotherapy
Presenter: Ming Huang Chen
Session: Poster Display session 2
Resources:
Abstract